Visunex rounds up $20M for newborn eye imaging system

Baby picture
Visunex, which makes wireless digital imaging systems to screen newborns for eye disorders, plans to launch another device in its PanoCam series later this year.

Visunex Medical Systems raised $20 million in a Series B round, which will expand its R&D and manufacturing operations. The company markets a wireless digital imaging system that screens for eye disorders in newborns.

The Fremont, California-based company markets the PanoCam suite of devices, wide-field digital imaging tools for newborns and infants.

The PanoCam LT system comprises an image-capturing device, review software and a color printer, which fit into a suitcase for easy transport. Images and data are transmitted wirelessly between the components and to the cloud.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Related: Gobiquity picks up Series B to advance smartphone amblyopia screening app

Its followup, the PanoCam Pro, scored FDA clearance last year, and Visunex plans to launch another device later this year, according to a statement.

"This new round of funding brings the total investment into Visunex Medical to $32 million, and will allow the company to expand manufacturing operations to meet the market demand,” said Visunex CEO Wei Su in the statement. “We will also increase our investment in R&D, including resources, to bring additional products and clinical options through the development pipeline and into the market.”

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.